oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes SELECT Trial PDF) Oral Semaglutide and Cardiovascular
Description
Keeping weight off isnt as simple as ignoring food cravings
Lower doses mean fewer side effects, lower medication costs, and easier long-term adherence
As analyzed by the recent meta-analysis of these trials, there is a 32% prevalence of heart-related diseases in T2DM patients
Oral semaglutide is generally considered for individuals with a Body Mass Index (BMI) of 30 or higher, or a BMI of 27 or higher when accompanied by weight-related health concerns
